Shateri Amiri Bahareh, Naserranjbar Mehrasa, Mirhaji AyAna, Hejrati Alireza, Hejrati Lina, Aliabadi Fatemeh
Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, University of Medical Sciences, Tehran, Iran.
School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Bioimpacts. 2024 Oct 27;15:29993. doi: 10.34172/bi.29993. eCollection 2025.
Pancreatic cancer, which results from the uncontrolled growth of pancreatic cells, is the fourth most frequent cause of cancer-related mortality in the United States. About 90% of instances of pancreatic cancer are pancreatic adenocarcinomas, and occasionally "pancreatic cancer" is used exclusively to describe this subtype. Nab-paclitaxel, gemcitabine, and FOLFIRINOX are examples of modern chemotherapeutic drugs that have the ability to quickly confer resistance in pancreatic tumor cells. Therefore, in order to treat this dreadful condition, it is essential to develop more effective medicines. Inhibition of the ubiquitin-proteasome system (UPS) causes pancreatic cancer cells to die apoptotically. In eukaryotes, UPS is an essential mechanism for protein breakdown. Pancreatic cancer cells are more susceptible to endoplasmic reticulum stress (endoplasmic reticulum [ER] stress) and apoptosis when treated with bortezomib, a proteasome inhibitor that is the first in this group of drugs approved for the treatment of cancer, especially multiple myeloma.
Searching through PubMed and Google Scholar and gathering data.
UPS is still a popular target for pancreatic cancer treatment among researchers. However, despite the favorable results of UPS-based therapies in vitro and in vivo, the clinical results are not as promising as expected.
A deep understanding of it, is essential to achieving the maximum results. In this review, we aim to look into the UPS along with searching for the novelist therapies for pancreatic adenocarcinoma based on manipulating it.
胰腺癌由胰腺细胞的无节制生长导致，是美国癌症相关死亡的第四大常见原因。约90%的胰腺癌病例为胰腺腺癌，偶尔“胰腺癌”仅用于描述此亚型。纳米白蛋白结合型紫杉醇、吉西他滨和FOLFIRINOX是现代化疗药物的例子，它们能够迅速使胰腺肿瘤细胞产生耐药性。因此，为了治疗这种可怕的疾病，开发更有效的药物至关重要。抑制泛素-蛋白酶体系统（UPS）会导致胰腺癌细胞凋亡。在真核生物中，UPS是蛋白质分解的重要机制。当用硼替佐米（一种蛋白酶体抑制剂，是该类药物中首个被批准用于治疗癌症，尤其是多发性骨髓瘤的药物）处理时，胰腺癌细胞对内质网应激（内质网应激）和凋亡更敏感。
通过PubMed和谷歌学术搜索并收集数据。
UPS仍然是研究人员治疗胰腺癌的热门靶点。然而，尽管基于UPS的疗法在体外和体内取得了良好效果，但临床结果并不像预期的那样有前景。
深入了解它对于取得最大效果至关重要。在本综述中，我们旨在研究UPS，并寻找基于对其进行调控的胰腺腺癌新疗法。
